U.S. market Closed. Opens in 21 hours 43 minutes

CVKD | Cadrenal Therapeutics, Inc. Common Stock Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 18.05 - 18.58
52 Week Range 5.40 - 22.90
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 9,812
Average Volume 43,873
Shares Outstanding 1,782,486
Market Cap 32,904,692
Sector Healthcare
Industry Biotechnology
IPO Date 2023-01-20
Valuation
Profitability
Growth
Health
P/E Ratio -2.11
Forward P/E Ratio N/A
EPS -8.73
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 4
Country USA
Website CVKD
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
*Chart delayed
Analyzing fundamentals for CVKD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CVKD Fundamentals page.

Watching at CVKD technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CVKD Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙